Building Europe’s Frontline Against Future Pandemics

• The European Clinical Research Alliance on Infectious Diseases (Ecraid) is a pan-European, not-for-profit network designed to maintain a "warm-base" research infrastructure, ensuring hospitals are constantly prepared for health crises.
• Unlike traditional methods that build systems from scratch during emergencies, Ecraid keeps research sites active, trained, and resourced at all times to enable immediate data collection and trial deployment.
• Adaptive platform trials are used to test multiple therapies simultaneously, allowing researchers to add new treatments into existing trials to accelerate results.

Key Objectives and Challenges

• Ecraid addresses two primary threats: emerging infectious diseases—exacerbated by climate change and increased global travel—and antimicrobial resistance, which is described as a "silent pandemic."
• Lessons from the 2009 H1N1 swine flu and COVID-19 pandemic highlighted that rapid response is impossible without established, pre-existing research infrastructure.

EU Funding and Structure

• The European Union provided foundational support through initiatives like COMBACTE and PREPARE, followed by a €30 million investment in 2021 for the ECRAID-Base project.
• This long-term funding transitioned Ecraid into a self-sustaining, not-for-profit organization supported by public and industry partnerships.

International Collaboration and Future Strategy

• Dr. Lennie Derde, the current CEO, underscores the importance of multinational collaboration based on her experience leading the European arm of the REMAP-CAP trial during COVID-19.
• The organization focuses on being data-driven, ensuring interoperability between GP clinics, emergency departments, and intensive care units.
• Future goals include building a "network of networks" across Europe to ensure research capacity remains active and responsive to evolving infectious threats.